A number of possible drugs, devices, and processes targeting various diseases have been developed by the different institutes under the Indian Council of Medical Research (ICMR) under the extramural research programmes, and have been placed for commercialisation.
- The All India Institute of Medical Sciences (AIIMS), New Delhi has developed hypoxia responsive promoters of Mycobacterium tuberculosis.The study provides a whole cell assay to monitor M. tuberculosis promoter activity and would find use in the screening of compounds that inhibit these promoters.
- Delhi University, South Campus, New Delhi has developed anti-tubercular drug targets relating to identification of the role of protein tyrosine phosphates (MptpA and MptpB) in the pathogenesis of Mycobacterium tuberculosis.
- Entomology Research Institute, Chennai, has developed a process for isolation of fraction from Adhatoda vasica leaves for anti-mycobacterial activity with no side effects. The novel compounds vasicine acetate and 2-acetylbenzylamine showed good anti-tubercular properties against M tuberculosis and their effect is comparable with standard drugs for curing TB, the note said.
- Indian Institute of Technology (IIT), New Delhi, has developed a copolymer compound — Styrene Maleic Anhydride (SMA) –used as male contraceptive. Phase I and phase II clinical trials have completed and restricted phase III clinical trial is underway. The institute also developed a process preparing the same injectable copolymer SMA.
- University of Kolkata has developed an anti-neoplastic compound and process for its preparation. The invention provides a novel anti-neoplastic compound and obtained from the skin extract of the Indian snake head fish, Channa striatus, locally known as shol fish. It also provides a process for the isolation of a novel anti-neoplastic agent useful for therapeutic application in neoplasia and as a biomedical research probe/tool.